Abstract 415P
Background
Blood-based MCED testing has emerged as a promising paradigm for earlier detection of cancer, which is associated with better outcomes. Little is known about the real-world performance of such assays in Asia. A ctDNA mutation-based MCED assay (LucenceINSIGHT), reports cancer signal (CS) status in plasma, and additionally predicts tissue-of-origin for up to 10 cancers where identifiable. We report here real-world results of the initial cohort.
Methods
Targeted ultrasensitive amplicon-based next-generation sequencing (NGS) with mirror barcodes is used to detect CS status by detecting cancer-associated mutations and viral DNA in 84 genes in plasma cell-free DNA (cfDNA). Matched white blood cell DNA was analyzed to exclude clonal hematopoiesis as a contributor. Consecutive results from 264 subjects (1/2023 - 6/2023) from Singapore, Hong Kong and Malaysia that underwent testing at a CAP-accredited, CLIA-certified laboratory were included in the analysis.
Results
were returned for 100% of subjects with a mean turnaround time of 14.1 calendar days. Mean age was 55.1 years (yrs) with 61.4% being male. CS-positive rate was 1.1% (3/264). All 3 CS-positive subjects were male, >40 years of age and were asymptomatic and without known cancer at screening. All 3 subsequently had neoplasms confirmed (locally advanced colon cancer, localized kidney cancer, and myeloproliferative neoplasm), for a specificity and PPV of 100%. 2 of 3 of these cases (kidney and myeloproliferative neoplasm) would not have been covered under traditional screening guidelines. One subject with CS-negative test results had a suspected cholangiocarcinoma at the point of test order, for an overall sensitivity of 75%.
Conclusions
We report initial experience with a cohort undergoing amplicon-based MCED testing in Asia, with a real-world CSD rate of 1.1%, consistent with previous ctDNA-based cancer screening studies in the USA. A majority of cases detected were not covered under traditional screening guidelines. These findings provide additional support for the use of ultrasensitive mutation-based assays for screening.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Lucence Diagnostics Pte Ltd.
Funding
Lucence Diagnostic Pte Ltd.
Disclosure
M. Pek, C. Hao, Z.Y. Wan, J. Poh, M. Tan: Financial Interests, Institutional, Full or part-time Employment: Lucence Diagnostics. M. Tan: Financial Interests, Institutional, Full or part-time Employment: Lucence Diagnostics; Financial Interests, Institutional, Stocks or ownership: Lucence Diagnostics. All other authors have declared no conflicts of interest.
Resources from the same session
551P - Real-world incidence and outcomes of immune-related adverse events in NSCLC patients
Presenter: Andrea Knox
Session: Poster Display
Resources:
Abstract
552P - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
Presenter: Yasushi Goto
Session: Poster Display
Resources:
Abstract
553P - Preceding plasma EGFR vs upfront tissue NGS for advanced NSCLC in the Chinese population: A single centre experience in Hong Kong
Presenter: Janet Du
Session: Poster Display
Resources:
Abstract
554P - Comparison of the analytical performance of endobronchial ultrasound-guided transbronchial needle aspiration and other sampling methods for the Oncomine Dx target test: An observational study
Presenter: Kazuhito Miyazaki
Session: Poster Display
Resources:
Abstract
555P - Quality of life in patients with stage IV non-small cell lung cancer and the influence of druggable mutations over time: A prospective, territory-wide study in Hong Kong
Presenter: Jason C S Ho
Session: Poster Display
Resources:
Abstract
556P - Results from the phase I study on efficacy and safety of iruplinalkib (WX-0593) for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who received prior second-generation ALK tyrosine kinase inhibitors (TKIs)
Presenter: xuezhi Hao
Session: Poster Display
Resources:
Abstract
557P - Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy
Presenter: Shasha Wang
Session: Poster Display
Resources:
Abstract
558P - Treatment duration and adherence of brigatinib as second-line treatment after crizotinib for ALK+ NSCLC in South Korea
Presenter: Jeong Eun Lee
Session: Poster Display
Resources:
Abstract
559P - Comprehensive survey of AACR GENIE database revealed a wide range of TMB distribution among all three classes (I, II, III) of BRAF mutated NSCLC
Presenter: Zhaohui Arter
Session: Poster Display
Resources:
Abstract
560P - Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC
Presenter: Chengdi Weng
Session: Poster Display
Resources:
Abstract